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Background: Transurethral laser therapy techniques are increasingly being used in the management of bladder
tumors. It has reportedly been associated with good outcomes in small case series. The objective of the present
study was to review the published literature and compare transurethral laser therapy for non–muscle-invasive
bladder cancer (NMIBC) and conventional transurethral resection of bladder tumor (TURBT).
Methods: We performed a systematic review and meta-analysis based on randomized controlled trials (RCTs) and
controlled clinical trials (CCTs) to assess the two techniques. The eligible RCTs and CCTs were identified in the
following electronic databases: PubMed, the Cochrane Central Register of Controlled Trials and Embase.
Results: Seven studies were included in this systematic review. The baseline characteristics of these studies are
comparable. We found no statistical difference between the two techniques regarding operative time. The intra- and
postoperative complications showed that the laser procedure was better than TURBT for NMIBC, including obturator
nerve reflex, bladder perforation, bladder irrigation rate, duration of catheterization and length of hospital stay. In
addition, the 2-year recurrence-free survival improved in the laser group than in the TURBT group.
Conclusions: Our systematic review and meta-analysis suggests that laser techniques are feasible, safe, effective
procedures that provide an alternative treatment for patients with NMIBC. Given that some limitations cannot be
overcome, well-designed RCTs are needed to confirm our findings.
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Bladder cancer is one of the most common malignant
diseases of the urinary tract system. According to the
American Cancer Society, an estimated 74,690 new cases
of bladder cancer and 15,580 bladder cancer–related
deaths occurred in 2014 [1]. Approximately 75% patients
with bladder cancer present with non-muscle-invasive
bladder cancer (NMIBC; formerly known as superficial
bladder cancer) that is confined to either the mucosa
(stage Ta, carcinoma in situ) or submucosa (stage T1) [2].
The current standard treatment for NMIBC is trans-
urethral resection of bladder tumor (TURBT), followed by
adjuvant intravesical chemotherapy or immunotherapy* Correspondence: hanpingwch@163.com
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unless otherwise stated.[2]. The goals of TURBT are to eradicate all visible tu-
mors, prevent tumor recurrence and prevent progression
to invasive or metastatic disease. However, when the le-
sions are located in the lateral bladder wall or around the
ureteral orifice, optimal penetration is difficult to con-
trol during TURBT, and complications such as bleed-
ing, bladder perforation and hydronephrosis can occur.
In addition, these procedures are more likely stimulate
the adjacent obturator nerve, which is in close proxi-
mity to the lateral bladder wall. This stimulation causes
obturator nerve reflex (ONR), leading to inadvertent
bleeding and bladder perforation [3].
New technologies, such as bipolar plasmakinetics and
laser surgery, have emerged to avoid these problems and
improve the efficacy of TURBT. Laser is widely used in
urologic surgery and has been proved to be safe, effective
and minimally invasive for NMIBC [4]. Examples of lasersThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Flow diagram of studies identified, included
and excluded.
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net (Nd:YAG), potassium titanyl phosphate (also known
as green-light laser), holmium YAG (Ho:YAG) and a 2-μm
continuous-wave laser (thulium:YAG (Tm:YAG) laser). Of
these, holmium and the 2-μm laser TURBT are the most
frequently applied treatments for NMIBC, and these
treatments result in satisfactory outcomes [5]. However,
because of insufficient well-documented evidence to date,
it remains unknown whether laser TURBT is an effective
and safe alternative to TURBT for NMIBC.
In recent years, several studies directly comparing
transurethral laser therapy and TURBT have been pub-
lished in an attempt to explore this issue. Although the
outcomes of NMIBC after transurethral laser treatment
were reported to be similar to those after TURBT in
terms of oncologic and perioperative outcomes, these
remain a matter of debate because results have been re-
stricted to small sample sizes and obtained from a single
research center. In addition, most studies have been
nonrandomized controlled trials (NRCTs). NRCTs com-
paring laser treatment for bladder tumors as well as
TURBT could either underestimate or exaggerate any true
differences between the two procedures. However, the
results of a systematic review and meta-analysis of well-
designed NRCTs during surgical procedures were proven
feasible and exactly similar to those of contemporaneous
randomized controlled trials (RCTs) [6,7]. Consequently,
we performed a systematic review of NRCTs using meta-
analysis to determine whether there were any differences
between the intraoperative and postoperative outcomes in
addition to oncologic outcomes between these two
approaches and determine whether transurethral laser
treatment techniques can be an appropriate alternatives to
TURBT.
Methods
This study doesn’t involve human subjects and does not
require Institutional Review Board review or consent. In
March 2014, PubMed, the Cochrane Central Register of
Controlled Trials (CENTRAL) (via Ovid) and EMBASE
(via Ovid) were searched using the following terms:
“urinary bladder neoplasm”, “transitional cell carcinoma”,
“bladder cancer”, “bladder tumor”, “urinary bladder
cancer” and “laser”. The article language was restricted
to English.
Two authors separately evaluated all the potentially eli-
gible studies without prior consideration of the results and
assessed the methodological quality. For a study to be
considered eligible, it had to meet the following criteria:
(1) The study was a RCT or a controlled clinical trial
(CCT); (2) the primary NMIBC had to be pathologically
confirmed; (3) the treatment intervention was transureth-
ral laser therapy (excluding Nd:YAG laser due to its not
commonly being used in bladder cancer and havingseveral drawbacks, such as deep-tissue penetration that
limits its use on filmy wall areas, particularly on the pos-
terior side and dome of the bladder) of the bladder tumor
versus conventional TURBT; (4) original data for dichot-
omous and continuous variables had to be provided or
calculated from the data source; and (5) measures of ob-
jective and/or subjective outcomes had to be clearly de-
fined. Studies were excluded if they met the following
criteria: (1) The study was not a RCT or CCT; (2) the
study was an animal study; (3) patients were diagnosed
with recurrent bladder cancer, muscle-invasive bladder
cancer, metastatic disease and/or upper urinary tract tu-
mors; (4) patients had previous TURBT or transurethral
resection of the prostate; and (5) there was combined use
of laser and TURBT.
The methodological quality of the included studies in
our meta-analysis was assessed in accordance with the
Cochrane Handbook [8]. We evaluated the quality of
these individual studies using the Downs and Black qual-
ity assessment method, in which a list of 27 criteria are
used to evaluate both RCTs and NRCTs [9]. This quality
assessment scale assesses study reports, external validity
and internal validity and has been ranked in the top six
quality assessment scales suitable for use in systematic
Table 1 Baseline characteristics of included trials




Age (yr.)* Male (%) Tumor
Multiplicity*
Tumor Size (cm)* Location(n) T Stage (n) Grade(n)
Lateral Other Ta CIS T1 PUNLMP Low High
Yang [11], 2014 Retrospective, B 18 KTP TURBT 28 32 45.3 42.5 78.6 78.1 NR NR N/A N/A 22 17 6 15 8 7 0 0 20 25 NR NR NR NR NR NR
Tao [12], 2013 Retrospective, C 17 HPS 74 66.4 81.08 1.52 2.1 62 12 50 1 23 9 60 5
TURBT 84 65.3 78.57 1.49 1.9 69 15 61 2 21 10 68 6
Liu [13], 2013 Prospective, B 20 2-micron 64 67.1 71.9 2.8 1.3 24 40 37 0 27 11 46 7
TURBT 56 66.3 71.4 2.7 1.2 21 35 34 0 22 10 41 5
Zhong [16], 2010 Retrospective, C 16 2-micron 30 68.30 NR 1.53 2.23 NR NR 23 2 5 4 21 5
HoLRBT 25 65.76 NR 1.40 1.38 NR NR 19 1 5 3 18 4
TURBT 42 66.26 NR 1.45 1.54 NR NR 30 4 8 7 26 9
Xishuang [14], 2010 Prospective, B 18 HoLRBT 64 72.5 81.3 2.0 1.85 25 39 36 5 23 5 39 20
TURBT 51 74.5 78.4 1.9 1.74 20 31 30 4 17 4 33 14
Zhu [15], 2008 Prospective, B 17 HoLRBT 101 NR 78.2 NR NR NR NR 67 5 34 NR NR NR
TURBT 111 NR 82.9 NR NR NR NR 70 7 41 NR NR NR
Muraro [17], 2005 Retrospective, C 16 HoLRBT 50 64.5 78 N/A NR NR NR 43 0 7 NR NR NR
TURBT 50 65.7 80 N/A NR NR NR 46 0 4 NR NR NR
PUNLMP = papillary urothelial neoplasms of low malignant potential; CIS = carcinoma in situ; KTP = Potassium-titanyl-phosphate laser; HPS = 120 W high performance system Green-light laser vaporization of bladder
tumor; HoLRBT = holmium laser resection of bladder tumor; TURBT = transurethral resection of bladder tumor; 2 micron = 2 micron continuous wave laser resection of bladder tumor; NR = not reported;
N/A = not applicable;


















Figure 2 Quality assessment. Chart summarizes our judgments
about each risk of bias item for each included study. References:
Liu et al. [13], Muraro et al. [17], Tao et al. [12], Xishuang et al. [14],
Yang et al. [11], Zhong et al. [16] and Zhu et al. [15].
Bai et al. World Journal of Surgical Oncology 2014, 12:301 Page 4 of 9
http://www.wjso.com/content/12/1/301reviews [10]. A higher score was associated with higher
study quality. The Downs and Black score ranges were
grouped into the following four quality levels: excellent
(26 to 28), good (20 to 25), fair (15 to 19) and poor
(<14). At the same time, a grading system (GRADE) [8]
was used to assess the quality of each study included in our
meta-analysis, which was based on the following five fac-
tors: (1) no limitations of the study design, (2) consistency
of the results, (3) directness of evidence, (4) sufficient data
and (5) minimal potential publication bias. The overall
quality of a systematic review was considered to be high if
multiple included studies with a low risk of bias provided
consistent results regarding outcome. The quality of evi-
dence was downgraded by one level if one of the above-
mentioned factors was not met. Similarly, if two or three
factors were not met, the level of evidence was downgraded
by two or three levels, respectively. Therefore, the GRADE
approach resulted in four levels of quality of evidence: high
(A), moderate (B), low (C) and very low (D).
Data extraction was independently performed by two
authors and was then cross checked. Any disagreement
between the extracting authors was resolved by consensus
of all authors. The primary outcome measures included
ONR rate, bladder perforation rate, and recurrence-free
survival, whereas the secondary outcomes included opera-
tive time, bladder irrigation rate, and the duration of
catheterization and length of hospital stay. In addition to
the abovementioned outcomes, additional data, including
the authors’ names, publication year, number of patients
and their age, tumor multiplicity, tumor size, and tumor
stage/grade, were extracted from each included studies
and recorded as baseline characteristics.
Statistical analysis was conducted using RevMan5.2.5.
The risk ratio (RR) was used for dichotomous variables,
and mean difference (MD) was used for continuous data,
both with 95% confidence intervals (CI). Methodological
heterogeneity was assessed during selection, and statis-
tical heterogeneity was measured using the χ2 test and I2
scores. If χ2 heterogeneity was reported as P > 0.1 and
I2 < 50%, heterogeneity was considered low. A fixed-
effects model was used to assess the data of included
studies with minimal or no heterogeneity. In contrast, a
random-effects model was applied. A P-value for signifi-
cance was set at <0.05.
Results
The literature search yielded 689 reports, of which 671
were excluded on the basis of title or abstract that was
irrelevant to the topic, and 8 were excluded from the
remaining 15 literature after reading the full text. There-
fore, data from seven studies were included in this sys-
tematic review. All of the included studies reported on
various outcomes that were suitable for pooling into a
meta-analysis. There were eight contrast trials, and onestudy included two contrast tests. Figure 1 reveals the
outcomes of the literature search. The baseline and gen-
eral characteristics of the included studies were ex-
tracted and are listed in Table 1. All seven study reports
included the tumor size, operation time, bladder irriga-
tion, duration of catheterization and length of hospital
stay, as well as follow-up data. Five studies included re-
ports on ONR [11-15], and six described bladder perfor-
ation [11-16]. All data from these studies that were
presented as means ± standard deviation or rates, which
allowed for a meta-analysis, were pooled and analyzed.
Based on the Cochrane Collaboration’s tool for asses-
sing risk of bias, the baseline characteristics of the in-
cluded studies were comparable. Table 1 presents the
demographics of the studies, including number of pa-
tients, age, sex, location, T stage and grade. There were
no significant differences between transurethral laser re-
section and TURBT in any of the demographic parame-
ters (P > 0.05). However, there were different levels of
bias (Figure 2). Most of the studies included in our ana-
lysis were retrospective [11,12,16,17], and two were
RCTs [13,15]. All included studies did not state that they
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blinded. The outcomes of the included studies were
clear, except for those on ONR and bladder perforation
[16,17]. Overall, four studies had low risk of bias, and
three [15-17] had medium risk of bias. The Downs and
Black quality assessment scores of all studies were >14.
The quality of results in research methodology evalu-
ation is listed in Table 1.
No statistical difference was found in operation time
between transurethral laser treatment and TURBT for
NMIBC (MD = −0.69, 95% CI [−1.62, 0.24], P = 0.14)
(Figure 3). Six studies have compared transurethral laser
management of bladder tumors with TURBT, bladder
irrigation, the duration of catheterization and length of
hospital stay, but these studies exhibited heterogeneity.
We repeated the sensitivity analysis for these studies and
obtained similar results. Using a random-effects model,
the results of meta-analysis showed significant differ-
ences between the two groups with regard to bladder
irrigation (RR = 0.36; 95% CI [0.19, 0.69], P = 0.002)Figure 3 Cumulative analysis of studies comparing laser and transurethr
data. (A) Operation time (minute). (B) Duration of catheterization (day). (C) Len
of bladder tumor. References: Liu et al. [13], Tao et al. [12], Xishuang et al. [14], Y(Figure 4), the duration of catheterization (MD = −1.26,
95% CI [−1.79, −0.73], P < 0.00001) (Figure 3) and length
of hospital stay (MD = −1.52, 95% CI [−1.83, −1.20],
P < 0.00001) (Figure 3). The two groups showed signifi-
cant differences regarding ONR (RR = 0.07, 95% CI
[0.02, 0.23], P < 0.0001) (Figure 4) and bladder perforation
(RR = 0.16, 95% CI [0.05, 0.54], P = 0.003) (Figure 4).
Although the 1-year recurrence-free survival did not sta-
tistically differ between the two groups (RR = 1.04, 95% CI
[0.98, 1.10], P = 0.22) (Figure 5), the 2-year recurrence-
free survival (RR = 1.13, 95% CI [1.04, 1.22], P = 0.002)
(Figure 5) improved in the laser group compared to the
TURBT group.
Discussion
TURBT is commonly used in the diagnosis and treat-
ment of primary NMIBC because it can provide ad-
equate tissue samples for pathological examination and
all visible tumors can be excised efficiently. However,
TURBT is associated with potential risks, including theal resection of bladder tumors with respect to perioperative clinical
gth of hospital stay (day). IV, Inverse variance; TURBT, Transurethral resection
ang et al. [11], Zhong et al. [16] and Zhu et al. [15].
Figure 4 Cumulative analysis of studies comparing laser and transurethral resection of bladder tumors with respect to intraoperative
complications. (A) Bladder irrigation. (B) Obturator nerve reflex. (C) Bladder perforation. M-H, Mantel-Haenszel; TURBT, Transurethral resection of bladder
tumor. References: Liu et al. [13], Muraro et al. [17], Tao et al. [12], Xishuang et al. [14], Yang et al. [11], Zhong et al. [16] and Zhu et al. [15].
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located in the lateral bladder wall, which may lead to
bladder perforation. Although the success rate of the
transperineal obturator nerve block to prevent adductor
muscle contractions during TURBT is 83.8% to 85.7%
[18], this approach still may not completely prevent the
occurrence of ONR. Fortunately, the development of
bipolar plasmakinetics and the advent of modern laser
therapy techniques have provided more alternatives to
TURBT for bladder tumors [12,14], which may avoid the
above-listed shortcomings.
The use of laser techniques in urology was first reported
by in 1978 Staehler et al. [19], who described the successful
destruction of bladder tumors using Nd:YAG laser surgery.
This laser is used mainly for the treatment of benign pros-
tatic hyperplasia [20]. The advent of new laser techniques
and improvements in conventional TURBT resulted in the
abolishment of Nd lasers in the treatment of bladdertumors [5]. Therefore, in our systematic review and meta-
analysis, we did not include Nd laser techniques; instead,
we analyzed only commonly used lasers, such as green
light, Ho:YAG and the 2-μm continuous-wave lasers.
Our review of the published data of seven comparative
studies suggested that the 2-year recurrence-free survival
of the laser group was better than that of the conven-
tional TURBT group for NMIBC. Compared with con-
ventional TURBT, laser techniques can be used to excise
tumors without contact, and effective coagulation using
laser vaporization can seal off the blood and lymph ves-
sels around the tumors and reduce the implanted metas-
tasis of tumor cells and distant tumor recurrence [21].
Furthermore, the use of laser combined with endoscopic
techniques can accurately excise tumors, significantly
reduce the blind areas and reduce the residual tumor. In
2001, laser techniques achieved the level of complete
and precise removal of tumors from the submucosa or
Figure 5 Cumulative analysis of studies comparing laser and transurethral resection of bladder tumors with respect to recurrence-free
survival. (A) 1-year recurrence-free survival. (B) 2-year recurrence-free survival. M-H, Mantel-Haenszel; TURBT, Transurethral resection of bladder tumor.
References: Liu et al. [13], Muraro et al. [17], Tao et al. [12], Xishuang et al. [14], Yang et al. [11], Zhong et al. [16] and Zhu et al. [15].
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uted to its dual functions of vaporization and resection,
which provided sufficient tissue for pathological examin-
ation to assess tumor grade and stage. They also afforded
a theoretical basis for follow-up treatments, except for
green-light laser, because all of the tumor was vaporized.
Some scholars deemed that the recurrence rate of laser
treatment for bladder tumors is lower than that of TURBT
because of an active immune effect of the laser techniques
[23]. In contrast, an inadequate resection depth of the
basal parts of tumors during TURBT to avoid bladder
perforation may have resulted in a higher recurrence rate
[24]. In addition, it is easier to form encrustation when
using electrocautery to stop bleeding during TURBT,
which may result in tumor cells remained in situ [25].
In our meta-analysis, intraoperative complications
were less frequently observed in the laser group than in
the TURBT group. Bladder perforation is the most
serious complication of TURBT, and the other major
causes are thermal injury and ONR during TURBT.
When TURBT was applied to remove lateral tumors, the
current flow passing through the obturator nerve may
cause ONR, which results in sudden muscle contractions
and bladder perforation. Furthermore, the temperature
ranged from 100°C to 300°C at the treatment site,
thereby causing thermal injury [26]. In contrast, when
laser was applied to remove the tumor tissue, no currentflow was produced during the procedure. This procedure
could not stimulate the obturator nerve, especially in
patients with NMIBC, because tumors were located in
the lateral bladder wall. Therefore, bladder perforation
induced by ONR can be avoided by using laser tech-
niques. In addition, thermal injury at the treatment site
is minimized, which could be attributed to the absence
of a strong local electrical field.
Laser techniques without deep penetration are less inva-
sive and therefore reduce pain perception and cause min-
imal bleeding. In addition, the power of the laser can be
adjusted according to tumor size. The use of a laser also
provides surgeons with a clearer tumor view. Further-
more, satisfactory hemostatic effects are obtained with a
laser, because it can form a coagulation zone of 1- to
2-mm thickness on the surface of the wounded tissue
[12]. Under these circumstances, a laser can effectively
avoid additional damage due to repeated stanch, reduce
bladder irrigation and shorten the catheterization time
and length of hospital stay. Therefore, patients have a high
degree of overall satisfaction with minimal complications.
When we pooled the included studies and assessed post-
operative complications and clinical data, we found some
heterogeneity. When we performed sensitivity analysis on
the included studies, similar results were obtained. This
may be explained by the observation that the patients were
not discharged until the final postoperative pathological
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[12] considered that most patients with a newly diagnosed
bladder cancer require a hospital stay until catheter
removal. However, we believe that different doctors have
different standards for bladder irrigation, catheter removal
and hospital discharge. Therefore, special considerations
have to be incorporated when data regarding bladder
irrigation, catheterization and hospitalization are pooled.
Compared with previous reviews [4,5], our meta-
analysis contained one RCT and more strict quality as-
sessment methods were used. We evaluated the quality
of these individual studies using the Downs and Black
quality assessment method and also evaluated the risk of
bias. Kramer et al. [5] published a systematic review, the
results of which showed that Ho:YAG and Tm:YAG
seem to offer alternatives in the treatment of bladder
cancer, but there is no limit on the types of studies
included and no quantitative analyses. In our review, the
studies were RCTs or CCTs, and we also conducted a
meta-analysis, the results of which showed that laser has
several advantages over conventional TURBT. Therefore,
compared with the results reported by Kramer et al., we
deem our results more reliable. The recent review by
Teng et al. [4], who compared only Ho:YAG laser with
conventional TURBT, showed that holmium laser is safe
and efficient for the treatment of NMIBC, with results
similar to ours. However, we also compared green-light
and Tm:YAG lasers with TURBT. Therefore, our research
is more comprehensive. However, we also acknowledge
that certain inherent limitations in the studies included in
our meta-analysis cannot be ignored when interpreting
our data. The main limitation of the present review is that
only seven studies of small patient cohorts were included,
and most of these were retrospective. Therefore, large-
scale and multicentered RCTs should be performed to
evaluate the safety and efficacy of lasers for NMIBC. Fur-
thermore, there were differences in the length of follow-
up periods, so the standard scheme and results from the
long-term follow-up studies are expected. Also, none of
the studies used a systematic classification system for
assessing complications. In other words, there was no
unified standard of bladder irrigation, catheter uproot and
hospital discharge in the included studies, which resulted
in heterogeneity in our pooled analysis. Nevertheless,
despite varying degrees of differences in the data from the
included studies, it is noteworthy that the results of each
study are meaningful. In the future, the major clinical
indices should have a unified standard, because only in
this way will studies become more comparable, resulting
in more convincing pooled analyses.
Conclusions
Based on the data included in our meta-analysis, trans-
urethral laser resection techniques offer improved safetyand tolerability as well as enhanced recurrence-free sur-
vival compared with TURBT for NMIBC. Therefore, laser
techniques are feasible, safe and effective procedures that
provide an alternative treatment for patients with NMIBC.
Larger, prospective, multicentered studies with a longer
follow-up period should be performed to reinforce the
present findings.
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